{"url_path":"/sec/cadl/8-k/2026-06-24/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001841387-26-000009-index.html","accession_number":"0001841387-26-000009","cik":"0001841387","ticker":"CADL","issuer_name":"Candel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001841387-26-000009-index.html","primary_entity_key":"0001841387","primary_entity_name":"Candel Therapeutics, Inc."},"word_count":372,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nCandel Therapeutics, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026. As of April 24, 2026, the record date for the Annual Meeting, there were 73,270,239 outstanding shares of the Company’s voting common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2026: (i) to elect four Class II directors, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, to serve until the Company’s 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).\n\nThe Company’s stockholders elected each of the Class II director nominees, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows:\n\n \n\n \n\n \n\nFor\n\n \n\nWithheld\n\n \n\nBroker Non-Votes\n\nEdward J. Benz, Jr., M.D.\n\n \n\n24,897,348\n\n \n\n6,796,622\n\n \n\n22,175,525\n\nPaul B. Manning\n\n \n\n31,591,618\n\n \n\n102,352\n\n \n\n22,175,525\n\nMaha Radhakrishnan, M.D.\n\n \n\n31,047,706\n\n \n\n646,264\n\n \n\n22,175,525\n\nPaul Peter Tak, M.D., Ph.D., FMedSci\n\n \n\n31,414,668\n\n \n\n279,302\n\n \n\n22,175,525\n\n \n\nThe Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n53,543,020\n\n \n\n238,508\n\n \n\n87,967\n\n \n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.\n\n \n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCandel Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 24, 2026\n\nBy:\n\n/s/ Paul Peter Tak\n\n \n\n \n\n \n\nPaul Peter Tak, M.D., Ph.D., FMedSci\nPresident and Chief Executive Officer"}